Pharma Focus Asia

Novartis Expands Biopharmaceutical Manufacturing Facility in Singapore

Saturday, March 16, 2024

Novartis has commenced the expansion of its biopharmaceutical manufacturing plant in Singapore, announcing a significant investment of US$256 million. This expansion aims to integrate digital and automation solutions to enhance manufacturing productivity, operational efficiency, and workforce skills. The focus of the expanded site will be on producing therapeutic antibody drugs to provide groundbreaking treatments to patients worldwide.

Mr. Heng Swee Keat, Deputy Prime Minister and Coordinating Minister for Economic Policies, emphasized the importance of continuous innovation in manufacturing for the biopharma sector. He highlighted Singapore's well-established biomedical ecosystem, expressing confidence in collaboration with global partners like Novartis to deliver innovative biologics products.

Steffen Lang, President of Operations at Novartis, underscored the growing significance of biotherapeutics in addressing patient needs. He mentioned the substantial growth in Novartis' early-stage biologics portfolio and emphasized the timely nature of the new facility in Singapore, slated to be operational by early 2026. Lang highlighted its role in strengthening the biopharmaceutical manufacturing and supply chain across Asia, as well as enhancing local capabilities and talent in Singapore.

The endeavor is expected to create 100 high-skilled job openings, contributing to the expansion of the local life science sector. Novartis is committed to investing in talent development, providing training for existing employees to excel in the digitalized and automated environment of the expanded facility.

The groundbreaking event was graced by Deputy Prime Minister Heng Swee Keat as the Guest-of-Honor, along with Frank Grütter, Swiss Ambassador to Singapore, and Ms. Cindy Koh, Executive Vice President of EDB, among others.

Novartis has maintained a strong partnership with Singapore since 1986, with over US$1 billion invested to uplift the nation's pharmaceutical manufacturing capabilities. The Novartis Singapore manufacturing site, established since 2002, has been pivotal in the company's biopharmaceutical production efforts, supported by the Singapore government.



magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024